Literature DB >> 19273203

Integrins and proximal signaling mechanisms in cardiovascular disease.

Hind Lal1, Suresh K Verma, Donald M Foster, Honey B Golden, John C Reneau, Linley E Watson, Hitesh Singh, David E Dostal.   

Abstract

Integrins are heterodimeric cell-surface molecules, which act as the principle mediators of molecular dialog between a cell and its extracellular matrix environment. In addition to their structural functions, integrins mediate signaling from the extracellular space into the cell through integrin-associated signaling and adaptor molecules such as FAK (focal adhesion kinase), ILK (integrin-linked kinase), PINCH (particularly interesting new cysteine-histidine rich protein) and Nck2 (non-catalytic (region of) tyrosine kinase adaptor protein-2). Via these molecules, integrin signaling tightly and cooperatively interacts with receptor tyrosine kinases (RTKs) signaling to regulate survival, proliferation and cell shape as well as polarity, adhesion, migration and differentiation. In the heart and blood vessels, the function and regulation of these molecules can be partially disturbed and thus contribute to cardiovascular diseases such as cardiac hypertrophy and atherosclerosis. In this review, we discuss the primary mechanisms of action and signaling of integrins in the cardiac and vascular system in normal and pathological states, as well as therapeutic strategies for targeting these systems (1).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273203     DOI: 10.2741/3381

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  28 in total

1.  ATP released from cardiac fibroblasts via connexin hemichannels activates profibrotic P2Y2 receptors.

Authors:  David Lu; Sahar Soleymani; Rohit Madakshire; Paul A Insel
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

Review 2.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.

Authors:  Thibaut Quillard; Peter Libby
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

Review 3.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

4.  Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans.

Authors:  Laurence Campens; Marjolijn Renard; Bram Trachet; Patrick Segers; Laura Muino Mosquera; Johan De Sutter; Lynn Sakai; Anne De Paepe; Julie De Backer
Journal:  Pediatr Res       Date:  2015-06-04       Impact factor: 3.756

Review 5.  Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease.

Authors:  Hind Lal; Firdos Ahmad; Shan Parikh; Thomas Force
Journal:  Circ J       Date:  2014-06-05       Impact factor: 2.993

6.  Inflammatory responses in the atria: should they stay or should they go?

Authors:  Heather S Duffy
Journal:  Heart Rhythm       Date:  2010-11-05       Impact factor: 6.343

7.  Cellular Communications in the Heart.

Authors:  Katerina Fountoulaki; Nikolaos Dagres; Efstathios K Iliodromitis
Journal:  Card Fail Rev       Date:  2015-10

8.  Cerebral inflammatory response and predictors of admission clinical grade after aneurysmal subarachnoid hemorrhage.

Authors:  Khalid A Hanafy; R Morgan Stuart; Luis Fernandez; J Michael Schmidt; Jan Claassen; Kiwon Lee; E Sander Connolly; Stephan A Mayer; Neeraj Badjatia
Journal:  J Clin Neurosci       Date:  2009-12-08       Impact factor: 1.961

Review 9.  The eNOS signalosome and its link to endothelial dysfunction.

Authors:  Mauro Siragusa; Ingrid Fleming
Journal:  Pflugers Arch       Date:  2016-05-17       Impact factor: 3.657

10.  Thrombospondins in the heart: potential functions in cardiac remodeling.

Authors:  Mark W M Schellings; Geert C van Almen; E Helene Sage; Stephane Heymans
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.